Back to top

Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss

Read MoreHide Full Article

Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.

Agios received FDA approval for Idhifa (enasidenib) in August 2017 for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. It is the first FDA-approved therapy for the given indication.

The company has several interesting candidates in its pipeline. Promising candidates in cancer pipeline includes IDH1 mutant inhibitor, AG-120 (ivosidenib) and a pan-IDH mutant inhibitor, AG-881. In December 2017, Agios submitted a new drug application (NDA) to the FDA for AG-120 which has been developed for treating patients with R/R AML and an IDH1 mutation.

Agios’ earnings performance so far has been strong with the company beating expectations in three of the last four reported quarters and missing in the other. Overall, the company has delivered an average positive beat of 4.48%.

Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Loss Wider: Agios posted wider-than-expected loss in the fourth quarter of 2017. Our consensus called for a loss of $1.65 per share, and the company reported a loss of $1.81. Reported loss was also wider than the year ago figure of $1.34.

Revenues Miss: Revenues in the reported quarter also came below expectations. Agios posted revenues of approximately $9.8 million, compared to our consensus estimate of $16 million. The revenues significantly decreased 56.6% from year ago figure of $22.6 million.

Key Stats: Research & development expenses were up 19.3% year over year to $77.2 million. General and administrative expenses increased 47.4% year over year to $22.7 million.

Share Price Impact: In-active in pre-market trading.

Check back later for our full write up on AGIO earnings report later!

Don’t Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks’ has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Agios Pharmaceuticals, Inc. (AGIO) - free report >>

More from Zacks Tale of the Tape

You May Like